| 1 | proton | 1,516 |
| 2 | virological | 1,513 |
| 3 | virologic | 1,210 |
| 4 | pain-free | 674 |
| 5 | serine | 488 |
| 6 | extended-spectrum | 315 |
| 7 | startle | 256 |
| 8 | nucleophilic | 148 |
| 9 | michael | 91 |
| 10 | ns3 | 74 |
| 11 | centrifugal | 66 |
| 12 | sensor-augmented | 66 |
| 13 | ns3/4a | 49 |
| 14 | postextrasystolic | 37 |
| 15 | 26s | 35 |
| 16 | eyeblink | 25 |
| 17 | chymotrypsin-like | 23 |
| 18 | postactivation | 21 |
| 19 | asas40 | 19 |
| 20 | prepotent | 17 |
| 21 | headache-free | 16 |
| 22 | post-extrasystolic | 15 |
| 23 | post-activation | 13 |
| 24 | lon | 11 |
| 25 | superovulatory | 11 |
| 26 | 60-kda | 10 |
| 27 | ctx-m-type | 10 |
| 28 | low-efficiency | 10 |
| 29 | na+-k+ | 10 |
| 30 | painfree | 10 |
| 31 | false-alarm | 9 |
| 32 | subtilisin-like | 9 |
| 33 | ascaris-type | 8 |
| 34 | aspartyl | 8 |
| 35 | elta | 8 |
| 36 | aza-michael | 7 |
| 37 | beta-end | 7 |
| 38 | metallo | 7 |
| 39 | n1p1 | 7 |
| 40 | nonboosted | 7 |
| 41 | tragal | 7 |
| 42 | vinylogous | 7 |
| 43 | cyclic-amp | 6 |
| 44 | gain/frequency | 6 |
| 45 | pole-mounted | 6 |
| 46 | tyrosyl-dna | 6 |
| 47 | ubiquitin-specific | 6 |
| 48 | vasodepressive | 6 |
| 49 | wf146 | 6 |
| 50 | cnn | 5 |
| 51 | exemestane-ovarian | 5 |
| 52 | micrococcal | 5 |
| 53 | photoparoxysmal | 5 |
| 54 | plasmablast | 5 |
| 55 | sfn-induced | 5 |
| 56 | tamoxifen-ovarian | 5 |
| 57 | β1-3 | 5 |
| 58 | 'proton | 4 |
| 59 | antipredator | 4 |
| 60 | drug-primed | 4 |
| 61 | insensibility | 4 |
| 62 | mini-osmotic | 4 |
| 63 | partial/no | 4 |
| 64 | spleen/pancreas | 4 |
| 65 | virologic/immunologic | 4 |
| 66 | δvo2/δwr | 4 |
| 67 | clements | 3 |
| 68 | clonidine-diuretic | 3 |
| 69 | complete+partial | 3 |
| 70 | digit-letter | 3 |
| 71 | exteroceptive | 3 |
| 72 | hcy-induced | 3 |
| 73 | head-twitch | 3 |
| 74 | high-efficient | 3 |
| 75 | i-aaa | 3 |
| 76 | ig-degrading | 3 |
| 77 | mc-specific | 3 |
| 78 | minor/localized | 3 |
| 79 | ns3-4a | 3 |
| 80 | oxa-type | 3 |
| 81 | perrier | 3 |
| 82 | pt-h₂ | 3 |
| 83 | response/treatment | 3 |
| 84 | running-stop-jump | 3 |
| 85 | shv-5 | 3 |
| 86 | virological/immunological | 3 |
| 87 | /antioxidant | 2 |
| 88 | 3c-like | 2 |
| 89 | asd+ | 2 |
| 90 | bithermia | 2 |
| 91 | channel-activating | 2 |
| 92 | ck-mm | 2 |
| 93 | emd-induced | 2 |
| 94 | executor | 2 |
| 95 | implant/crown | 2 |
| 96 | integron-associated | 2 |
| 97 | interunit | 2 |
| 98 | keratinolytic | 2 |
| 99 | l3/p23 | 2 |
| 100 | leakage-free | 2 |
| 101 | lgp-induced | 2 |
| 102 | lowering-cholesterol | 2 |
| 103 | luminescence-based | 2 |
| 104 | m-aaa | 2 |
| 105 | madrs-defined | 2 |
| 106 | methionine-for-valine | 2 |
| 107 | mortality/clinical | 2 |
| 108 | ns3-ns4a | 2 |
| 109 | ns3/4 | 2 |
| 110 | okp-a | 2 |
| 111 | pet-defined | 2 |
| 112 | plasma-insulin | 2 |
| 113 | post-ingn-225 | 2 |
| 114 | postseizure | 2 |
| 115 | radioadaptive | 2 |
| 116 | response/no | 2 |
| 117 | site-2 | 2 |
| 118 | startle-like | 2 |
| 119 | task-negative | 2 |
| 120 | tissue-degrading | 2 |
| 121 | treatment-maintained | 2 |
| 122 | two-cough | 2 |
| 123 | ubiquitin/26s | 2 |
| 124 | ubp3-dependent | 2 |
| 125 | undulation | 2 |
| 126 | 'tragal | 1 |
| 127 | -bronchodilator | 1 |
| 128 | -to-leu | 1 |
| 129 | /verbal | 1 |
| 130 | 1/pro-inflammatory | 1 |
| 131 | 2-allergic | 1 |
| 132 | 3-hydroxy-4-methoxy | 1 |
| 133 | 39-kda | 1 |
| 134 | 45-fs | 1 |
| 135 | 5-scale | 1 |
| 136 | 6-fluoro | 1 |
| 137 | 6/12-week | 1 |
| 138 | a1r-mediated | 1 |
| 139 | acee-induced | 1 |
| 140 | acr50-crp | 1 |
| 141 | acra-acrb-tolc | 1 |
| 142 | aiia-dose | 1 |
| 143 | alt-lowering | 1 |
| 144 | amp-c | 1 |
| 145 | anti-cysteine | 1 |
| 146 | anti-impulsive | 1 |
| 147 | antilipopolysaccharide | 1 |
| 148 | antimony-bismuth | 1 |
| 149 | aorta-exaggerated | 1 |
| 150 | apoptosis-executive | 1 |
| 151 | avr1-mediated | 1 |
| 152 | azidation-michael | 1 |
| 153 | baseline.in | 1 |
| 154 | bath/water | 1 |
| 155 | bhp-induced | 1 |
| 156 | bi-leaflet | 1 |
| 157 | bo3-po4 | 1 |
| 158 | camp/pka-mediated | 1 |
| 159 | caspatag | 1 |
| 160 | cassumunar-mediated | 1 |
| 161 | catheter-computer | 1 |
| 162 | cb1r-dependent | 1 |
| 163 | chromatin-dependent | 1 |
| 164 | clinical/surgical | 1 |
| 165 | cold-hardened | 1 |
| 166 | complete/near-complete | 1 |
| 167 | control-standardized | 1 |
| 168 | cortisol-awakening | 1 |
| 169 | cross-orientation | 1 |
| 170 | crt+af | 1 |
| 171 | cyclic-amp-specific | 1 |
| 172 | cysteine-aspartate-specific | 1 |
| 173 | d102h | 1 |
| 174 | daoist | 1 |
| 175 | dd1-mediated | 1 |
| 176 | ddavp-mediated | 1 |
| 177 | degree-of-methylether | 1 |
| 178 | devices.in | 1 |
| 179 | diminished/sedative | 1 |
| 180 | direct-dose | 1 |
| 181 | docetaxelfor | 1 |
| 182 | donor-stabilized | 1 |
| 183 | dorsiflexions | 1 |
| 184 | drug-transport | 1 |
| 185 | easl-based | 1 |
| 186 | eflux | 1 |
| 187 | electrodermic | 1 |
| 188 | endoscopy-proton | 1 |
| 189 | enos-hyperactivation | 1 |
| 190 | epa-mediated | 1 |
| 191 | eurocollins | 1 |
| 192 | ev68-encoded | 1 |
| 193 | exa3-1-mediated | 1 |
| 194 | exposure-clinical | 1 |
| 195 | fatigue-improvement | 1 |
| 196 | fearful-face | 1 |
| 197 | fgf-induced | 1 |
| 198 | forehead-eyelid-nasal | 1 |
| 199 | formation/michael | 1 |
| 200 | four-centered | 1 |
| 201 | fp-mediated | 1 |
| 202 | gentamicin-sulfate-resistant | 1 |
| 203 | gnl | 1 |
| 204 | groups-viral | 1 |
| 205 | gβγ-plcβ-pkc-dependent | 1 |
| 206 | hassessing | 1 |
| 207 | hexanol-degrading | 1 |
| 208 | hidromeiotic | 1 |
| 209 | hiv-viremia | 1 |
| 210 | hsod1-mediated | 1 |
| 211 | hydrolysis/thio-michael | 1 |
| 212 | hyper-stable | 1 |
| 213 | h→ch3 | 1 |
| 214 | i-to-f | 1 |
| 215 | ic-selective | 1 |
| 216 | il17-a | 1 |
| 217 | immunostimulative | 1 |
| 218 | incognita-specific | 1 |
| 219 | indomethacin-mediated | 1 |
| 220 | inflammatory-marker | 1 |
| 221 | intent-to-treat-time-to-loss-of-virological | 1 |
| 222 | invasive-off | 1 |
| 223 | iron-associated | 1 |
| 224 | ischaemia-mediated | 1 |
| 225 | k86r | 1 |
| 226 | ketoamide | 1 |
| 227 | laboratory-instructed | 1 |
| 228 | ldlc-lowering | 1 |
| 229 | leg-axis | 1 |
| 230 | letter-digit | 1 |
| 231 | limb-withdrawal | 1 |
| 232 | log-term | 1 |
| 233 | low-magnetic | 1 |
| 234 | lysine-to-asparagine | 1 |
| 235 | methylxantine | 1 |
| 236 | mfn-2-mediated | 1 |
| 237 | microaxial | 1 |
| 238 | mir-34-mediated | 1 |
| 239 | multicatalytic | 1 |
| 240 | n'-tetraoctyl-3-oxo-pentane | 1 |
| 241 | n90a | 1 |
| 242 | nano-lc | 1 |
| 243 | nobiletin-induced | 1 |
| 244 | non-chordal | 1 |
| 245 | non-concentric | 1 |
| 246 | non-satisfactory | 1 |
| 247 | normal/suppressed/no | 1 |
| 248 | o-phenol | 1 |
| 249 | ofclinical | 1 |
| 250 | ofleukocyte | 1 |
| 251 | omicronbjective | 1 |
| 252 | oxa-10-like | 1 |
| 253 | oxa-2-like | 1 |
| 254 | p20l | 1 |
| 255 | p489s | 1 |
| 256 | parental-proxy | 1 |
| 257 | phenylpropoxy | 1 |
| 258 | photodriven | 1 |
| 259 | physically-induced | 1 |
| 260 | pii-independent | 1 |
| 261 | pinprick-evoked | 1 |
| 262 | placebo.dose | 1 |
| 263 | polygalacto | 1 |
| 264 | post-socket | 1 |
| 265 | ppd-sf-mediated | 1 |
| 266 | presentation-verbal | 1 |
| 267 | prophenoloxidase-activating | 1 |
| 268 | proscribes | 1 |
| 269 | proteasomal-mediated | 1 |
| 270 | pyridazinone-based | 1 |
| 271 | r64w | 1 |
| 272 | recist/crabb | 1 |
| 273 | relapse/defaulter/treatment | 1 |
| 274 | ritonvair-boosted | 1 |
| 275 | saba.the | 1 |
| 276 | sb216763-mediated | 1 |
| 277 | scale.insulin | 1 |
| 278 | semi-conserved | 1 |
| 279 | serin | 1 |
| 280 | serine-to-alanine | 1 |
| 281 | seroprotection/vaccine | 1 |
| 282 | sfn-stimulated | 1 |
| 283 | single-speed | 1 |
| 284 | sleep-habit | 1 |
| 285 | staff-programmed | 1 |
| 286 | suitable-coronal | 1 |
| 287 | sumo/ub-sumo | 1 |
| 288 | supramucosal | 1 |
| 289 | t-to-c | 1 |
| 290 | testosterone/anabolic | 1 |
| 291 | thereaputic | 1 |
| 292 | thiostrepton-induced | 1 |
| 293 | thromboprophylaxis.in | 1 |
| 294 | time-to-loss-of-virologic | 1 |
| 295 | treg-mediated | 1 |
| 296 | trichorionic-triamniotic | 1 |
| 297 | tumour-marker | 1 |
| 298 | ua-lowering | 1 |
| 299 | valine-to-glutamate | 1 |
| 300 | valine-to-methionine | 1 |
| 301 | vegf-c-activating | 1 |
| 302 | virilogical | 1 |
| 303 | virusological | 1 |
| 304 | vpu-dependent | 1 |
| 305 | w50r | 1 |
| 306 | weather-health | 1 |
| 307 | week-3 | 1 |
| 308 | yawn/sigh | 1 |
| 309 | ∼180° | 1 |
| 1 | 'proton | 4 |
| 2 | 'tragal | 1 |
| 3 | -bronchodilator | 1 |
| 4 | -to-leu | 1 |
| 5 | /antioxidant | 2 |
| 6 | /verbal | 1 |
| 7 | 1/pro-inflammatory | 1 |
| 8 | 2-allergic | 1 |
| 9 | 26s | 35 |
| 10 | 3-hydroxy-4-methoxy | 1 |
| 11 | 39-kda | 1 |
| 12 | 3c-like | 2 |
| 13 | 45-fs | 1 |
| 14 | 5-scale | 1 |
| 15 | 6-fluoro | 1 |
| 16 | 6/12-week | 1 |
| 17 | 60-kda | 10 |
| 18 | a1r-mediated | 1 |
| 19 | acee-induced | 1 |
| 20 | acr50-crp | 1 |
| 21 | acra-acrb-tolc | 1 |
| 22 | aiia-dose | 1 |
| 23 | alt-lowering | 1 |
| 24 | amp-c | 1 |
| 25 | anti-cysteine | 1 |
| 26 | anti-impulsive | 1 |
| 27 | antilipopolysaccharide | 1 |
| 28 | antimony-bismuth | 1 |
| 29 | antipredator | 4 |
| 30 | aorta-exaggerated | 1 |
| 31 | apoptosis-executive | 1 |
| 32 | asas40 | 19 |
| 33 | ascaris-type | 8 |
| 34 | asd+ | 2 |
| 35 | aspartyl | 8 |
| 36 | avr1-mediated | 1 |
| 37 | aza-michael | 7 |
| 38 | azidation-michael | 1 |
| 39 | baseline.in | 1 |
| 40 | bath/water | 1 |
| 41 | beta-end | 7 |
| 42 | bhp-induced | 1 |
| 43 | bi-leaflet | 1 |
| 44 | bithermia | 2 |
| 45 | bo3-po4 | 1 |
| 46 | camp/pka-mediated | 1 |
| 47 | caspatag | 1 |
| 48 | cassumunar-mediated | 1 |
| 49 | catheter-computer | 1 |
| 50 | cb1r-dependent | 1 |
| 51 | centrifugal | 66 |
| 52 | channel-activating | 2 |
| 53 | chromatin-dependent | 1 |
| 54 | chymotrypsin-like | 23 |
| 55 | ck-mm | 2 |
| 56 | clements | 3 |
| 57 | clinical/surgical | 1 |
| 58 | clonidine-diuretic | 3 |
| 59 | cnn | 5 |
| 60 | cold-hardened | 1 |
| 61 | complete+partial | 3 |
| 62 | complete/near-complete | 1 |
| 63 | control-standardized | 1 |
| 64 | cortisol-awakening | 1 |
| 65 | cross-orientation | 1 |
| 66 | crt+af | 1 |
| 67 | ctx-m-type | 10 |
| 68 | cyclic-amp | 6 |
| 69 | cyclic-amp-specific | 1 |
| 70 | cysteine-aspartate-specific | 1 |
| 71 | d102h | 1 |
| 72 | daoist | 1 |
| 73 | dd1-mediated | 1 |
| 74 | ddavp-mediated | 1 |
| 75 | degree-of-methylether | 1 |
| 76 | devices.in | 1 |
| 77 | digit-letter | 3 |
| 78 | diminished/sedative | 1 |
| 79 | direct-dose | 1 |
| 80 | docetaxelfor | 1 |
| 81 | donor-stabilized | 1 |
| 82 | dorsiflexions | 1 |
| 83 | drug-primed | 4 |
| 84 | drug-transport | 1 |
| 85 | easl-based | 1 |
| 86 | eflux | 1 |
| 87 | electrodermic | 1 |
| 88 | elta | 8 |
| 89 | emd-induced | 2 |
| 90 | endoscopy-proton | 1 |
| 91 | enos-hyperactivation | 1 |
| 92 | epa-mediated | 1 |
| 93 | eurocollins | 1 |
| 94 | ev68-encoded | 1 |
| 95 | exa3-1-mediated | 1 |
| 96 | executor | 2 |
| 97 | exemestane-ovarian | 5 |
| 98 | exposure-clinical | 1 |
| 99 | extended-spectrum | 315 |
| 100 | exteroceptive | 3 |
| 101 | eyeblink | 25 |
| 102 | false-alarm | 9 |
| 103 | fatigue-improvement | 1 |
| 104 | fearful-face | 1 |
| 105 | fgf-induced | 1 |
| 106 | forehead-eyelid-nasal | 1 |
| 107 | formation/michael | 1 |
| 108 | four-centered | 1 |
| 109 | fp-mediated | 1 |
| 110 | gain/frequency | 6 |
| 111 | gentamicin-sulfate-resistant | 1 |
| 112 | gnl | 1 |
| 113 | groups-viral | 1 |
| 114 | gβγ-plcβ-pkc-dependent | 1 |
| 115 | hassessing | 1 |
| 116 | hcy-induced | 3 |
| 117 | head-twitch | 3 |
| 118 | headache-free | 16 |
| 119 | hexanol-degrading | 1 |
| 120 | hidromeiotic | 1 |
| 121 | high-efficient | 3 |
| 122 | hiv-viremia | 1 |
| 123 | hsod1-mediated | 1 |
| 124 | hydrolysis/thio-michael | 1 |
| 125 | hyper-stable | 1 |
| 126 | h→ch3 | 1 |
| 127 | i-aaa | 3 |
| 128 | i-to-f | 1 |
| 129 | ic-selective | 1 |
| 130 | ig-degrading | 3 |
| 131 | il17-a | 1 |
| 132 | immunostimulative | 1 |
| 133 | implant/crown | 2 |
| 134 | incognita-specific | 1 |
| 135 | indomethacin-mediated | 1 |
| 136 | inflammatory-marker | 1 |
| 137 | insensibility | 4 |
| 138 | integron-associated | 2 |
| 139 | intent-to-treat-time-to-loss-of-virological | 1 |
| 140 | interunit | 2 |
| 141 | invasive-off | 1 |
| 142 | iron-associated | 1 |
| 143 | ischaemia-mediated | 1 |
| 144 | k86r | 1 |
| 145 | keratinolytic | 2 |
| 146 | ketoamide | 1 |
| 147 | l3/p23 | 2 |
| 148 | laboratory-instructed | 1 |
| 149 | ldlc-lowering | 1 |
| 150 | leakage-free | 2 |
| 151 | leg-axis | 1 |
| 152 | letter-digit | 1 |
| 153 | lgp-induced | 2 |
| 154 | limb-withdrawal | 1 |
| 155 | log-term | 1 |
| 156 | lon | 11 |
| 157 | low-efficiency | 10 |
| 158 | low-magnetic | 1 |
| 159 | lowering-cholesterol | 2 |
| 160 | luminescence-based | 2 |
| 161 | lysine-to-asparagine | 1 |
| 162 | m-aaa | 2 |
| 163 | madrs-defined | 2 |
| 164 | mc-specific | 3 |
| 165 | metallo | 7 |
| 166 | methionine-for-valine | 2 |
| 167 | methylxantine | 1 |
| 168 | mfn-2-mediated | 1 |
| 169 | michael | 91 |
| 170 | microaxial | 1 |
| 171 | micrococcal | 5 |
| 172 | mini-osmotic | 4 |
| 173 | minor/localized | 3 |
| 174 | mir-34-mediated | 1 |
| 175 | mortality/clinical | 2 |
| 176 | multicatalytic | 1 |
| 177 | n'-tetraoctyl-3-oxo-pentane | 1 |
| 178 | n1p1 | 7 |
| 179 | n90a | 1 |
| 180 | na+-k+ | 10 |
| 181 | nano-lc | 1 |
| 182 | nobiletin-induced | 1 |
| 183 | non-chordal | 1 |
| 184 | non-concentric | 1 |
| 185 | non-satisfactory | 1 |
| 186 | nonboosted | 7 |
| 187 | normal/suppressed/no | 1 |
| 188 | ns3 | 74 |
| 189 | ns3-4a | 3 |
| 190 | ns3-ns4a | 2 |
| 191 | ns3/4 | 2 |
| 192 | ns3/4a | 49 |
| 193 | nucleophilic | 148 |
| 194 | o-phenol | 1 |
| 195 | ofclinical | 1 |
| 196 | ofleukocyte | 1 |
| 197 | okp-a | 2 |
| 198 | omicronbjective | 1 |
| 199 | oxa-10-like | 1 |
| 200 | oxa-2-like | 1 |
| 201 | oxa-type | 3 |
| 202 | p20l | 1 |
| 203 | p489s | 1 |
| 204 | pain-free | 674 |
| 205 | painfree | 10 |
| 206 | parental-proxy | 1 |
| 207 | partial/no | 4 |
| 208 | perrier | 3 |
| 209 | pet-defined | 2 |
| 210 | phenylpropoxy | 1 |
| 211 | photodriven | 1 |
| 212 | photoparoxysmal | 5 |
| 213 | physically-induced | 1 |
| 214 | pii-independent | 1 |
| 215 | pinprick-evoked | 1 |
| 216 | placebo.dose | 1 |
| 217 | plasma-insulin | 2 |
| 218 | plasmablast | 5 |
| 219 | pole-mounted | 6 |
| 220 | polygalacto | 1 |
| 221 | post-activation | 13 |
| 222 | post-extrasystolic | 15 |
| 223 | post-ingn-225 | 2 |
| 224 | post-socket | 1 |
| 225 | postactivation | 21 |
| 226 | postextrasystolic | 37 |
| 227 | postseizure | 2 |
| 228 | ppd-sf-mediated | 1 |
| 229 | prepotent | 17 |
| 230 | presentation-verbal | 1 |
| 231 | prophenoloxidase-activating | 1 |
| 232 | proscribes | 1 |
| 233 | proteasomal-mediated | 1 |
| 234 | proton | 1,516 |
| 235 | pt-h₂ | 3 |
| 236 | pyridazinone-based | 1 |
| 237 | r64w | 1 |
| 238 | radioadaptive | 2 |
| 239 | recist/crabb | 1 |
| 240 | relapse/defaulter/treatment | 1 |
| 241 | response/no | 2 |
| 242 | response/treatment | 3 |
| 243 | ritonvair-boosted | 1 |
| 244 | running-stop-jump | 3 |
| 245 | saba.the | 1 |
| 246 | sb216763-mediated | 1 |
| 247 | scale.insulin | 1 |
| 248 | semi-conserved | 1 |
| 249 | sensor-augmented | 66 |
| 250 | serin | 1 |
| 251 | serine | 488 |
| 252 | serine-to-alanine | 1 |
| 253 | seroprotection/vaccine | 1 |
| 254 | sfn-induced | 5 |
| 255 | sfn-stimulated | 1 |
| 256 | shv-5 | 3 |
| 257 | single-speed | 1 |
| 258 | site-2 | 2 |
| 259 | sleep-habit | 1 |
| 260 | spleen/pancreas | 4 |
| 261 | staff-programmed | 1 |
| 262 | startle | 256 |
| 263 | startle-like | 2 |
| 264 | subtilisin-like | 9 |
| 265 | suitable-coronal | 1 |
| 266 | sumo/ub-sumo | 1 |
| 267 | superovulatory | 11 |
| 268 | supramucosal | 1 |
| 269 | t-to-c | 1 |
| 270 | tamoxifen-ovarian | 5 |
| 271 | task-negative | 2 |
| 272 | testosterone/anabolic | 1 |
| 273 | thereaputic | 1 |
| 274 | thiostrepton-induced | 1 |
| 275 | thromboprophylaxis.in | 1 |
| 276 | time-to-loss-of-virologic | 1 |
| 277 | tissue-degrading | 2 |
| 278 | tragal | 7 |
| 279 | treatment-maintained | 2 |
| 280 | treg-mediated | 1 |
| 281 | trichorionic-triamniotic | 1 |
| 282 | tumour-marker | 1 |
| 283 | two-cough | 2 |
| 284 | tyrosyl-dna | 6 |
| 285 | ua-lowering | 1 |
| 286 | ubiquitin-specific | 6 |
| 287 | ubiquitin/26s | 2 |
| 288 | ubp3-dependent | 2 |
| 289 | undulation | 2 |
| 290 | valine-to-glutamate | 1 |
| 291 | valine-to-methionine | 1 |
| 292 | vasodepressive | 6 |
| 293 | vegf-c-activating | 1 |
| 294 | vinylogous | 7 |
| 295 | virilogical | 1 |
| 296 | virologic | 1,210 |
| 297 | virologic/immunologic | 4 |
| 298 | virological | 1,513 |
| 299 | virological/immunological | 3 |
| 300 | virusological | 1 |
| 301 | vpu-dependent | 1 |
| 302 | w50r | 1 |
| 303 | weather-health | 1 |
| 304 | week-3 | 1 |
| 305 | wf146 | 6 |
| 306 | yawn/sigh | 1 |
| 307 | β1-3 | 5 |
| 308 | δvo2/δwr | 4 |
| 309 | ∼180° | 1 |
| 1 | asd+ | 2 |
| 2 | na+-k+ | 10 |
| 3 | asas40 | 19 |
| 4 | n1p1 | 7 |
| 5 | site-2 | 2 |
| 6 | β1-3 | 5 |
| 7 | week-3 | 1 |
| 8 | l3/p23 | 2 |
| 9 | h→ch3 | 1 |
| 10 | ns3 | 74 |
| 11 | ns3/4 | 2 |
| 12 | bo3-po4 | 1 |
| 13 | shv-5 | 3 |
| 14 | post-ingn-225 | 2 |
| 15 | wf146 | 6 |
| 16 | il17-a | 1 |
| 17 | okp-a | 2 |
| 18 | n90a | 1 |
| 19 | ns3-4a | 3 |
| 20 | ns3/4a | 49 |
| 21 | ns3-ns4a | 2 |
| 22 | i-aaa | 3 |
| 23 | m-aaa | 2 |
| 24 | 60-kda | 10 |
| 25 | 39-kda | 1 |
| 26 | hiv-viremia | 1 |
| 27 | bithermia | 2 |
| 28 | tyrosyl-dna | 6 |
| 29 | elta | 8 |
| 30 | recist/crabb | 1 |
| 31 | t-to-c | 1 |
| 32 | amp-c | 1 |
| 33 | incognita-specific | 1 |
| 34 | mc-specific | 3 |
| 35 | cysteine-aspartate-specific | 1 |
| 36 | ubiquitin-specific | 6 |
| 37 | cyclic-amp-specific | 1 |
| 38 | virologic/immunologic | 4 |
| 39 | virologic | 1,210 |
| 40 | time-to-loss-of-virologic | 1 |
| 41 | 2-allergic | 1 |
| 42 | nucleophilic | 148 |
| 43 | testosterone/anabolic | 1 |
| 44 | post-extrasystolic | 15 |
| 45 | postextrasystolic | 37 |
| 46 | electrodermic | 1 |
| 47 | non-concentric | 1 |
| 48 | low-magnetic | 1 |
| 49 | clonidine-diuretic | 3 |
| 50 | hidromeiotic | 1 |
| 51 | trichorionic-triamniotic | 1 |
| 52 | mini-osmotic | 4 |
| 53 | thereaputic | 1 |
| 54 | multicatalytic | 1 |
| 55 | keratinolytic | 2 |
| 56 | nano-lc | 1 |
| 57 | acra-acrb-tolc | 1 |
| 58 | emd-induced | 2 |
| 59 | acee-induced | 1 |
| 60 | fgf-induced | 1 |
| 61 | sfn-induced | 5 |
| 62 | nobiletin-induced | 1 |
| 63 | thiostrepton-induced | 1 |
| 64 | lgp-induced | 2 |
| 65 | bhp-induced | 1 |
| 66 | hcy-induced | 3 |
| 67 | physically-induced | 1 |
| 68 | ev68-encoded | 1 |
| 69 | single-speed | 1 |
| 70 | pinprick-evoked | 1 |
| 71 | drug-primed | 4 |
| 72 | staff-programmed | 1 |
| 73 | cold-hardened | 1 |
| 74 | treatment-maintained | 2 |
| 75 | madrs-defined | 2 |
| 76 | pet-defined | 2 |
| 77 | four-centered | 1 |
| 78 | luminescence-based | 2 |
| 79 | pyridazinone-based | 1 |
| 80 | easl-based | 1 |
| 81 | integron-associated | 2 |
| 82 | iron-associated | 1 |
| 83 | exa3-1-mediated | 1 |
| 84 | dd1-mediated | 1 |
| 85 | hsod1-mediated | 1 |
| 86 | avr1-mediated | 1 |
| 87 | mfn-2-mediated | 1 |
| 88 | sb216763-mediated | 1 |
| 89 | mir-34-mediated | 1 |
| 90 | ischaemia-mediated | 1 |
| 91 | camp/pka-mediated | 1 |
| 92 | epa-mediated | 1 |
| 93 | ppd-sf-mediated | 1 |
| 94 | treg-mediated | 1 |
| 95 | proteasomal-mediated | 1 |
| 96 | indomethacin-mediated | 1 |
| 97 | fp-mediated | 1 |
| 98 | ddavp-mediated | 1 |
| 99 | a1r-mediated | 1 |
| 100 | cassumunar-mediated | 1 |
| 101 | sfn-stimulated | 1 |
| 102 | aorta-exaggerated | 1 |
| 103 | laboratory-instructed | 1 |
| 104 | sensor-augmented | 66 |
| 105 | pole-mounted | 6 |
| 106 | ritonvair-boosted | 1 |
| 107 | nonboosted | 7 |
| 108 | semi-conserved | 1 |
| 109 | control-standardized | 1 |
| 110 | minor/localized | 3 |
| 111 | donor-stabilized | 1 |
| 112 | beta-end | 7 |
| 113 | fearful-face | 1 |
| 114 | ketoamide | 1 |
| 115 | antilipopolysaccharide | 1 |
| 116 | leakage-free | 2 |
| 117 | headache-free | 16 |
| 118 | pain-free | 674 |
| 119 | painfree | 10 |
| 120 | saba.the | 1 |
| 121 | oxa-10-like | 1 |
| 122 | oxa-2-like | 1 |
| 123 | 3c-like | 2 |
| 124 | startle-like | 2 |
| 125 | subtilisin-like | 9 |
| 126 | chymotrypsin-like | 23 |
| 127 | 5-scale | 1 |
| 128 | hyper-stable | 1 |
| 129 | startle | 256 |
| 130 | n'-tetraoctyl-3-oxo-pentane | 1 |
| 131 | seroprotection/vaccine | 1 |
| 132 | anti-cysteine | 1 |
| 133 | lysine-to-asparagine | 1 |
| 134 | methionine-for-valine | 2 |
| 135 | serine-to-alanine | 1 |
| 136 | valine-to-methionine | 1 |
| 137 | serine | 488 |
| 138 | methylxantine | 1 |
| 139 | oxa-type | 3 |
| 140 | ctx-m-type | 10 |
| 141 | ascaris-type | 8 |
| 142 | postseizure | 2 |
| 143 | aiia-dose | 1 |
| 144 | direct-dose | 1 |
| 145 | placebo.dose | 1 |
| 146 | valine-to-glutamate | 1 |
| 147 | complete/near-complete | 1 |
| 148 | ofleukocyte | 1 |
| 149 | anti-impulsive | 1 |
| 150 | vasodepressive | 6 |
| 151 | diminished/sedative | 1 |
| 152 | task-negative | 2 |
| 153 | immunostimulative | 1 |
| 154 | omicronbjective | 1 |
| 155 | ic-selective | 1 |
| 156 | radioadaptive | 2 |
| 157 | exteroceptive | 3 |
| 158 | apoptosis-executive | 1 |
| 159 | i-to-f | 1 |
| 160 | crt+af | 1 |
| 161 | invasive-off | 1 |
| 162 | caspatag | 1 |
| 163 | tissue-degrading | 2 |
| 164 | ig-degrading | 3 |
| 165 | hexanol-degrading | 1 |
| 166 | cortisol-awakening | 1 |
| 167 | ua-lowering | 1 |
| 168 | ldlc-lowering | 1 |
| 169 | alt-lowering | 1 |
| 170 | hassessing | 1 |
| 171 | vegf-c-activating | 1 |
| 172 | prophenoloxidase-activating | 1 |
| 173 | channel-activating | 2 |
| 174 | d102h | 1 |
| 175 | head-twitch | 3 |
| 176 | yawn/sigh | 1 |
| 177 | two-cough | 2 |
| 178 | weather-health | 1 |
| 179 | antimony-bismuth | 1 |
| 180 | 6/12-week | 1 |
| 181 | eyeblink | 25 |
| 182 | p20l | 1 |
| 183 | presentation-verbal | 1 |
| 184 | /verbal | 1 |
| 185 | micrococcal | 5 |
| 186 | virilogical | 1 |
| 187 | virological/immunological | 3 |
| 188 | virological | 1,513 |
| 189 | intent-to-treat-time-to-loss-of-virological | 1 |
| 190 | virusological | 1 |
| 191 | clinical/surgical | 1 |
| 192 | exposure-clinical | 1 |
| 193 | mortality/clinical | 2 |
| 194 | ofclinical | 1 |
| 195 | non-chordal | 1 |
| 196 | tragal | 7 |
| 197 | 'tragal | 1 |
| 198 | centrifugal | 66 |
| 199 | complete+partial | 3 |
| 200 | microaxial | 1 |
| 201 | photoparoxysmal | 5 |
| 202 | suitable-coronal | 1 |
| 203 | groups-viral | 1 |
| 204 | forehead-eyelid-nasal | 1 |
| 205 | supramucosal | 1 |
| 206 | limb-withdrawal | 1 |
| 207 | michael | 91 |
| 208 | aza-michael | 7 |
| 209 | azidation-michael | 1 |
| 210 | hydrolysis/thio-michael | 1 |
| 211 | formation/michael | 1 |
| 212 | gnl | 1 |
| 213 | o-phenol | 1 |
| 214 | lowering-cholesterol | 2 |
| 215 | aspartyl | 8 |
| 216 | ck-mm | 2 |
| 217 | false-alarm | 9 |
| 218 | log-term | 1 |
| 219 | extended-spectrum | 315 |
| 220 | exemestane-ovarian | 5 |
| 221 | tamoxifen-ovarian | 5 |
| 222 | photodriven | 1 |
| 223 | baseline.in | 1 |
| 224 | devices.in | 1 |
| 225 | thromboprophylaxis.in | 1 |
| 226 | plasma-insulin | 2 |
| 227 | scale.insulin | 1 |
| 228 | serin | 1 |
| 229 | cnn | 5 |
| 230 | undulation | 2 |
| 231 | cross-orientation | 1 |
| 232 | post-activation | 13 |
| 233 | enos-hyperactivation | 1 |
| 234 | postactivation | 21 |
| 235 | lon | 11 |
| 236 | proton | 1,516 |
| 237 | 'proton | 4 |
| 238 | endoscopy-proton | 1 |
| 239 | implant/crown | 2 |
| 240 | metallo | 7 |
| 241 | sumo/ub-sumo | 1 |
| 242 | normal/suppressed/no | 1 |
| 243 | response/no | 2 |
| 244 | partial/no | 4 |
| 245 | 6-fluoro | 1 |
| 246 | polygalacto | 1 |
| 247 | cyclic-amp | 6 |
| 248 | running-stop-jump | 3 |
| 249 | acr50-crp | 1 |
| 250 | w50r | 1 |
| 251 | k86r | 1 |
| 252 | degree-of-methylether | 1 |
| 253 | perrier | 3 |
| 254 | tumour-marker | 1 |
| 255 | inflammatory-marker | 1 |
| 256 | bath/water | 1 |
| 257 | digit-letter | 3 |
| 258 | catheter-computer | 1 |
| 259 | docetaxelfor | 1 |
| 260 | antipredator | 4 |
| 261 | -bronchodilator | 1 |
| 262 | executor | 2 |
| 263 | δvo2/δwr | 4 |
| 264 | 26s | 35 |
| 265 | ubiquitin/26s | 2 |
| 266 | p489s | 1 |
| 267 | spleen/pancreas | 4 |
| 268 | proscribes | 1 |
| 269 | 45-fs | 1 |
| 270 | leg-axis | 1 |
| 271 | eurocollins | 1 |
| 272 | dorsiflexions | 1 |
| 273 | clements | 3 |
| 274 | vinylogous | 7 |
| 275 | post-socket | 1 |
| 276 | bi-leaflet | 1 |
| 277 | sleep-habit | 1 |
| 278 | letter-digit | 1 |
| 279 | interunit | 2 |
| 280 | /antioxidant | 2 |
| 281 | gentamicin-sulfate-resistant | 1 |
| 282 | ubp3-dependent | 2 |
| 283 | gβγ-plcβ-pkc-dependent | 1 |
| 284 | chromatin-dependent | 1 |
| 285 | cb1r-dependent | 1 |
| 286 | vpu-dependent | 1 |
| 287 | pii-independent | 1 |
| 288 | high-efficient | 3 |
| 289 | fatigue-improvement | 1 |
| 290 | response/treatment | 3 |
| 291 | relapse/defaulter/treatment | 1 |
| 292 | prepotent | 17 |
| 293 | drug-transport | 1 |
| 294 | plasmablast | 5 |
| 295 | daoist | 1 |
| 296 | -to-leu | 1 |
| 297 | r64w | 1 |
| 298 | eflux | 1 |
| 299 | low-efficiency | 10 |
| 300 | gain/frequency | 6 |
| 301 | superovulatory | 11 |
| 302 | 1/pro-inflammatory | 1 |
| 303 | non-satisfactory | 1 |
| 304 | insensibility | 4 |
| 305 | 3-hydroxy-4-methoxy | 1 |
| 306 | phenylpropoxy | 1 |
| 307 | parental-proxy | 1 |
| 308 | pt-h₂ | 3 |
| 309 | ∼180° | 1 |